Triple negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of Oncology

BMC Women's Health

Volumn 12, Issue , 2012, Pages

  Rais, Ghizlane ^a   Raissouni, Soundouss ^a   Aitelhaj, Meryem ^a   Rais, Fadoi ^a   Naciri, Sara ^a   Khoyaali, Siham ^a   Abahssain, Halima ^a   Bensouda, Youssef ^a   Khannoussi, Basma ^a   Mrabti, Hind ^a   Errihani, Hassan ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Morocco)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL FEATURE; DRUG RESPONSE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MOROCCO; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXILLA; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, MEDULLARY; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; MASTECTOMY; MIDDLE AGED; MOROCCO; NEOPLASM GRADING; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84867021643     PISSN: None     EISSN: 14726874     Source Type: Journal    
DOI: 10.1186/1472-6874-12-35     Document Type: Article

References (39)

1. Rebecca S, Elizabeth W, Otis B, Ahmedin J. Cancer Statistics, 2011 CA. Cancer J Clin 2011, 61:212-236.
2. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
3. Sorlie T, Perou CM, Tibsirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
4. Perou CM, Jeffrey SS, Van de Rijn M, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 1999, 96:9212-9217. 10.1073/pnas.96.16.9212, 17759, 10430922.
5. Bertucci F, Finetti P, Birnbaum D. Basal breast cancer: a complex and deadly molecular subtype. Curr Mol Med 2012, 12:96-110. 10.2174/156652412798376134, 3343384, 22082486.
6. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, et al. Race, breast cancer subtypes, and survival in the carolina breast cancer study. JAMA 2006, 295:2492-2502. 10.1001/jama.295.21.2492, 16757721.
7. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13:4429-4434. 10.1158/1078-0432.CCR-06-3045, 17671126.
8. Amirikia KC, Paul M, Jason B, Newman LA. Higher population-based incidence rates of triple-negative breast cancer among young african-american women. Cancer 2011, 117:2747-2753. 10.1002/cncr.25862, 21656753.
9. Fernando L-M, et al. Triple-negative breast cancer in hispanic patients high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer 2011, 117:3658-3669. 10.1002/cncr.25961, 21387260.
10. Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African- American and caucasian patients. Cancer 2007, 110:876-884. 10.1002/cncr.22836, 17620276.
11. Amend K, Hicks D, Ambrosone C. Breast cancer in African- American women: differences in tumor biology from European- American women. Cancer Res 2006, 66:8327-8330. 10.1158/0008-5472.CAN-06-1927, 16951137.
12. Whitworth A. New research suggests access, genetic differences play role in high minority cancer death rate. J Natl Cancer Inst 2006, 98:669. 10.1093/jnci/djj223, 16705120.
13. Akasbi Y, Sanae B, Fouad A, Kawtar Z, Joutei KA, Afaf A, Omar EL M. Clinicopathological, therapeutic and prognostic features of the triple-negative tumors in moroccan breast cancer patients (experience of Hassan II university hospital in Fez). BMC Research Notes 2011, 4:500. 10.1186/1756-0500-4-500, 3226450, 22088140.
14. Chevallier B, Roche H, Olivier JP, et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 1993, 16:223-228. 10.1097/00000421-199306000-00006, 8338056.
15. Trivers KF, Mary Jo L, Porter PL, Liff JM, Flagg EW, Coates RJ, William Eley J. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 2009, 20:1071-1108. 10.1007/s10552-009-9331-1, 19343511.
16. Brinton LA, Daling JR, Liff JM, et al. Oral contraceptives and breast cancer risk among younger women. J Natl Cancer Inst 1995, 87:827-835. 10.1093/jnci/87.11.827, 7791232.
17. Dolle JM, Daling JR, White E, et al. Risk factors for triplenegative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev 2009, 18:1157-1166. 10.1158/1055-9965.EPI-08-1005, 2754710, 19336554.
18. Gupta PB, Proia D, Cingoz O, et al. Systemic stromal effects of estrogen promote the growth of estrogen receptornegative cancers. Cancer Res 2007, 67:2062-2071. 10.1158/0008-5472.CAN-06-3895, 17332335.
19. Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 2008, 14:8010-8018. 10.1158/1078-0432.CCR-08-1208, 19088017.
20. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, et al. Incidence and outcome of BRCA mutations inunselected patients with triple receptor-negative breast cancer. Clin Cancer Res 2011, 17:1082-1089. 10.1158/1078-0432.CCR-10-2560, 3048924, 21233401.
21. Venkitaraman R. Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features. Expert Rev Anticancer Ther 2010, 10(2):199-207. 10.1586/era.09.189, 20131996.
22. Anders CK, Winer EP, Ford JM, Dent R, Silver DP, Sledge GW, et al. Poly (ADP-ribose) polymerase inhibition: targeted therapy for triple negative breast cancer. Clin Cancer Res 2010, 16:4702-4710. 10.1158/1078-0432.CCR-10-0939, 2948607, 20858840.
23. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase intumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134. 10.1056/NEJMoa0900212, 19553641.
24. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple negative breast cancer-current status and future directions. Ann Oncol 2009, 20:1913-1927. 10.1093/annonc/mdp492, 19901010.
25. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007, 109:25-32. 10.1002/cncr.22381, 17146782.
26. Dawson SJ, Provenzano E, Caldas C. Triple negative breast cancers: clinical and prognostic implications. Eur J Cancer 2009, 45(Suppl 1):27-40.
27. Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006, 24:5652-5657. 10.1200/JCO.2006.06.5664, 17116942.
28. Cornelia L, Chafika M, Hess KR, Fabrice A, Attila T, Mejia JA, Fraser Symmans W, Gonzalez-Angulo AM, Bryan H, Marjorie G, Massimo C, Hortobagyi GN, Lajos P. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275-1281.
29. Bellati F, Visconti V, Napoletano C, Antonilli M, Frati L, Panici PB, Nuti M. Immunology of gynecologic neoplasms: analysis of the prognostic significance of the immune status. Curr Cancer Drug Targets 2009, 9(4):541-565. 10.2174/156800909788486722, 19519321.
30. Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010, 28:105-113. 10.1200/JCO.2009.23.7370, 19917869.
31. Bellati F, Napoletano C, Gasparri M, Benedetti Panici P, Nuti M. Immunologic systemic effect of neoadjuvant chemotherapy requires investigation before tumor-associated lymphocytes can be introduced in breast cancer treatment algorithm. J Clin Oncol 2010, 28(27):e471-e472. 10.1200/JCO.2010.27.9984, 20585098.
32. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676. 10.1056/NEJMoa072113, 18160686.
33. von Minckwitz G, , et al. German Breast Group and the Arbeitsgemeinschaft Gynäkologische Onkologie-Breast Study Groups Neoadjuvant chemotherapy and bevacizumab for HER2-Negative Breast. Cancer N Engl J Med 2012, 366:299-309. German Breast Group and the Arbeitsgemeinschaft Gynäkologische Onkologie-Breast Study Groups.
34. Federica C, et al. Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials. J Exp Clin Cancer Res 2011, 30:54. 10.1186/1756-9966-30-54, 3120715, 21569417.
35. Tutt A, Robson M, Garber JE, et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol 2009, 27(18 suppl). Abstract CRA501.
36. O'Shaughnessy J, Osborne C, Pippen J, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011, 364:3. 10.1056/NEJMp1012997, 21142690.
37. O'Shaughnessy J, Schwartzberg LS, Danso MA, et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC) (abstract 1007). J Clin Oncol 2011, 29:81s. Abstract available online at http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=78038 (Accessed on July 08, 2011).
38. Carey LA, Rugo HS, Marcom PK, et al. TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer. J Clin Oncol 2012, 30:2615. 10.1200/JCO.2010.34.5579, 22665533.
39. O'Shaughnessy J, Weckstein DJ, Vukeelja SJ, et al. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer [abstract 308] 2007, San Antonio Breast Cancer Symposium, San Antonio, Texas.